ClinicaliQ Trial Snapshot
- Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2) — Recruiting • Oncology • NCT07243262.
- What is being tested: A non-invasive breath test that detects volatile organic compounds (VOCs) produced by pancreatic cancer cells, aiming to enable earlier detection of pancreatic ductal adenocarcinoma.
- Patient eligibility overview: The trial includes patients with suspected or confirmed pancreatic cancer alongside control groups, allowing comparison of VOC profiles between diseased and healthy individuals to establish diagnostic accuracy.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The investigators are developing a non-invasive breath test to help us detect pancreatic cancer earlier. The test detects small molecules called volatile organic compounds that are made by pancreatic cancers. Pancreatic cancer is a rare disease but patients are often diagnosed at a late stage because their symptoms are the same as those of many common illnesses. This makes it hard for doctors to know which patients need to be tested for pancreatic cancer. If the investigators find pancreatic cancer at a late stage, it reduces the number of treatment…
Eligibility Snapshot
- : * Adult participants ≥ 18 years old * Referral from primary care according to the urgent suspected cancer referral guidelines for potential underlying pancreatic cancer, or referral directly to a pancreatic cancer multidisciplinary team meeting
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.